RxDoctor Payments Data

Sara Wallace

Family · Florence, SCNPI 1750908174

Payments from drug & device makers

$4,258in general payments, 2019–2025

Across 254 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$947
  • Johnson & Johnson$520
  • Amgen$466
  • GSK$410
  • AstraZeneca$319
  • Aurinia Pharma U.S., Inc.$250
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$4,20799%
  • Education$511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,258 in reported general payments places this provider in the 90th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$25,107
Medicare patients
119
Services billed
423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab149$1,109,569
Enbrel SureclickEtanercept104$764,424
RinvoqUpadacitinib72$502,255
Xeljanz XrTofacitinib Citrate46$277,588
Humira PenAdalimumab33$227,598
KevzaraSarilumab49$216,229
Enbrel MiniEtanercept26$202,954
Cimzia (2 Pack)Certolizumab Pegol13$80,139
BenlystaBelimumab16$75,584
Actemra ActpenTocilizumab13$61,405
RasuvoMethotrexate/Pf19$17,149
Hydroxychloroquine Sulfate283$8,008
MethotrexateMethotrexate Sodium382$7,000
Leflunomide92$5,999
Febuxostat37$2,874

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$947$502,25572 claims
SanofiKevzara$44$216,22949 claims
UCB, Inc.Cimzia (2 Pack)$205$80,13913 claims
GSKBenlysta$410$75,58416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,248 family providers in South Carolina.

Other family in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →